SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.

Shandong Buchang Pharmaceuticals Co., Ltd.

603858

CNE100002FV6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
15.85 ^CNY	-7.26%		-5.20%	-6.82%

Apr. 25	Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shandong Buchang Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.

December 12, 2023

The Board of Directors of Shandong Buchang Pharmaceuticals Co., Ltd. has authorized a buyback plan on December 13, 2023.

Latest news about Shandong Buchang Pharmaceuticals Co., Ltd.

Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023.	Apr. 01	CI
Buchang Pharma Obtains Green Light to Trial Gastric Cancer Drug Combination	Feb. 28	MT
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023.	Jan. 02	CI
Buchang Pharma’s Drugs Retain National Medical Insurance Coverage	Dec. 15	MT
Shandong Buchang Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 360 million worth of its shares.	Dec. 13	CI
Shandong Buchang Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.	Dec. 12	CI
Buchang Pharma's Unit Gets Nod to Test Colorectal Cancer Drug	Nov. 09	MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) and Xi Chong agreed to acquire 14% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd.,Hu Cunchao, Li Hui, and Hu Cunchao for CNY 0.	23-09-06	CI
Buchang Pharma Unit Gets Nod to Trial Cancer Treatment	23-09-04	MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Selling Expenses of Chinese Listed Pharma Companies About 1.5x Higher Than Net Profits in 2022	23-08-10	MT
Buchang Pharmaceuticals to Set Up Medical Device Subsidiary	23-08-08	MT
Buchang Pharma Unit Gets Nod to Make Amendments to Diabetes Drug	23-07-14	MT
Buchang Pharmaceuticals to Invest 223 Million Yuan Into Old Factory Upgrade	23-07-13	MT
Buchang Pharma's Unit Passes Regulator's Good Manufacturing Practice Evaluation	23-07-05	MT
Zhao Yunhua agreed to acquire a 90% stake in Buchang Taoyiyun Health Technology Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. for CNY 1.	23-06-28	CI
Ningbo Buchang Medical Technology Co., Ltd. announced that it expects to receive CNY 3 million in funding from Shandong Buchang Pharmaceuticals Co., Ltd., Shaanxi Deju Bowen Health Technology Co., Ltd.	23-06-26	CI
Buchang Pharma Unit Passes Regulatory Inspection	23-06-22	MT
Buchang Pharma Unit Gets Nod for Flu Vaccine Trials in China	23-06-20	MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Changrui Biotechnology Co., Ltd. announced that it has received CNY 64 million in funding from Shandong Buchang Pharmaceuticals Co., Ltd.	23-03-13	CI

Chart Shandong Buchang Pharmaceuticals Co., Ltd.

Duration

Period

Chart Shandong Buchang Pharmaceuticals Co., Ltd.

More charts

SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Companyâs main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.40%	1.38B

Alternative Medicine